William Blair Issues Positive Outlook for Xencor Earnings

Key Points

• William Blair analysts have upgraded their Q3 2025 earnings per share (EPS) estimate for Xencor, expecting it to be ($0.83), an improvement from their previous estimate of ($0.89), and they maintain an "Outperform" rating on the stock.
• In its latest earnings report, Xencor posted ($0.41) EPS, significantly beating the consensus estimate of ($0.78), with a revenue of $43.61 million, reflecting an 82.4% increase year-over-year.
• Xencor's stock is facing mixed ratings from analysts, with reports of lowered price targets from major firms, resulting in an overall average rating of "Moderate Buy" based on a target price of $26.43.

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Investment analysts at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for shares of Xencor in a report released on Wednesday, August 6th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of ($0.83) for the quarter, up from their previous estimate of ($0.89). William Blair has a "Outperform" rating on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor's Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.90) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.39) EPS, FY2027 earnings at ($3.24) EPS and FY2028 earnings at ($3.34) EPS.

A number of other research analysts have also recently commented on XNCR. Barclays decreased their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. Wells Fargo & Company cut their target price on Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Finally, Wedbush cut their target price on Xencor from $31.00 to $26.00 and set an "outperform" rating on the stock in a research report on Thursday, August 7th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $26.43.

Xencor Stock Down 3.7%

XNCR traded down $0.29 during trading on Monday, reaching $7.44. The company's stock had a trading volume of 194,560 shares, compared to its average volume of 767,628. The company has a market cap of $530.26 million, a price-to-earnings ratio of -3.13 and a beta of 0.89. The firm has a fifty day simple moving average of $8.58 and a two-hundred day simple moving average of $10.74. Xencor has a 1 year low of $6.92 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The firm had revenue of $43.61 million for the quarter, compared to analyst estimates of $22.59 million. During the same period last year, the company posted ($1.07) EPS. Xencor's quarterly revenue was up 82.4% compared to the same quarter last year.

Insider Buying and Selling at Xencor

In related news, Director Kurt A. Gustafson sold 2,993 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director owned 20,183 shares of the company's stock, valued at $186,087.26. This represents a 12.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard J. Ranieri sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This represents a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,194 shares of company stock worth $103,209 over the last quarter. 4.76% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. HighVista Strategies LLC lifted its holdings in shares of Xencor by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company's stock worth $262,000 after acquiring an additional 1,362 shares during the period. iSAM Funds UK Ltd bought a new position in shares of Xencor during the 2nd quarter worth about $122,000. WINTON GROUP Ltd lifted its holdings in Xencor by 6.1% during the 2nd quarter. WINTON GROUP Ltd now owns 91,241 shares of the biopharmaceutical company's stock valued at $717,000 after purchasing an additional 5,271 shares during the last quarter. Cerity Partners LLC bought a new position in Xencor during the 2nd quarter valued at about $195,000. Finally, Jump Financial LLC lifted its holdings in Xencor by 151.6% during the 2nd quarter. Jump Financial LLC now owns 126,972 shares of the biopharmaceutical company's stock valued at $998,000 after purchasing an additional 76,499 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.